Management Credibility Analysis
Upcoming Catalysts
Verified event feedCompany profile
No description available
- Chief executive
- Not disclosed
- Headquarters
- ELSE-KROENER STRASSE 1, BAD HOMBURG, 2M
- Founded
- Not disclosed
📈 Company Timeline
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in Fresenius Medical Care AG.
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in Fresenius Medical Care AG.
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in Fresenius Medical Care AG.
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in Fresenius Medical Care AG.
Capital Structure & Financial Position
Financial strength and liquidity analysisSource: SEC EDGAR company facts (opens in a new tab) Balance sheet dated
Peer Comparison - Health Care
| Company | Price | Market Cap |
|---|---|---|
| LLY - Eli Lilly and Company |
$1,276.13
Yahoo Finance |
$1.20T |
| JNJ - Johnson & Johnson |
$256.74
Yahoo Finance |
$618.71B |
| ABBV - AbbVie Inc. |
$284.80
Yahoo Finance |
$503.28B |
| UNH - UnitedHealth Group Incorporated |
$418.43
Yahoo Finance |
$375.58B |
| MRK - Merck & Co., Inc. |
$148.55
Yahoo Finance |
$366.50B |
📋 Corporate Actions
Recent and upcoming corporate eventsFinancials
Financial statements and key metrics analysis| Quarter | Revenue (USD) | Operating income | Net income | Diluted EPS (USD) | Filed |
|---|---|---|---|---|---|
| Q3 2016 | $4.60B | $669.94M | $333.18M | Unavailable | 6-K · 27 Oct 2016 |
| Q2 2016 | $4.42B | $641.09M | $293.95M | Unavailable | 6-K · 2 Aug 2016 |
| Q1 2016 | $4.21B | $540.29M | $228.02M | $0.75 | 6-K · 3 May 2016 |
| Q3 2015 | $4.23B | $613.53M | $262.32M | $0.86 | 6-K · 27 Oct 2016 |
| Q2 2015 | $4.20B | $546.96M | $240.77M | Unavailable | 6-K · 2 Aug 2016 |
| Q3 2010 | $3.06B | $493.25M | $247.79M | $0.82 | 6-K · 3 Nov 2010 |
Analyst Consensus
Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 19.90–25.80 Ratings are third-party opinions, not advice.
💰 Upcoming Dividends
Next dividend paymentsGuidance Evolution
💼 Director Transactions
Recent insider activityTop Shareholders
Source: Nasdaq institutional holdings (opens in a new tab) Observed · 1 day ago